AAAAAA

   
Results: 1-10 |
Results: 10
A PHASE-I AND PHARMACOKINETIC STUDY OF TALLIMUSTINE [PNU152241 (FCE-24517)] IN PATIENTS WITH ADVANCED CANCER
Authors: WEISS GR POGGESI I ROCCHETTI M DEMARIA D MOONEYHAM T REILLY D VITEK LV WHALEY F PATRICIA E VONHOFF DD ODWYER P
Citation: Gr. Weiss et al., A PHASE-I AND PHARMACOKINETIC STUDY OF TALLIMUSTINE [PNU152241 (FCE-24517)] IN PATIENTS WITH ADVANCED CANCER, Clinical cancer research, 4(1), 1998, pp. 53-59
A PHASE-I AND PHARMACOKINETIC STUDY OF TALLIMUSTINE [PNU152241 (FCE-24517)] IN PATIENTS WITH ADVANCED CANCER
Authors: WEISS GR POGGESI I ROCCHETTI M DEMARIA D MOONEYHAM T REILLY D VITEK LV WHALEY F PATRICIA E VONHOFF DD ODWYER P
Citation: Gr. Weiss et al., A PHASE-I AND PHARMACOKINETIC STUDY OF TALLIMUSTINE [PNU152241 (FCE-24517)] IN PATIENTS WITH ADVANCED CANCER, Clinical cancer research, 4(1), 1998, pp. 53-59
PHASE-II STUDY OF N-PHOSPHONACETYL-L-ASPARTATE, RECOMBINANT INTERFERON-ALPHA, AND FLUOROURACIL INFUSION IN ADVANCED SQUAMOUS-CELL CARCINOMAOF THE HEAD AND NECK
Authors: LANGER CJ SCHAEBLER D SAUTER E DEMARIA D JOHNSON C REILLY DM CLARK J LEIGHTON J AKS C LITWIN S RIDGE JA
Citation: Cj. Langer et al., PHASE-II STUDY OF N-PHOSPHONACETYL-L-ASPARTATE, RECOMBINANT INTERFERON-ALPHA, AND FLUOROURACIL INFUSION IN ADVANCED SQUAMOUS-CELL CARCINOMAOF THE HEAD AND NECK, Head & neck, 20(5), 1998, pp. 385-391
A PHASE-I TRIAL OF IRINOTECAN AND TOMUDEX ON AN EVERY 3 WEEK SCHEDULE
Authors: STEVENSON JP DEMARIA D REDLINGER M HILLER K MITCHELL E ROSE L FRIEDLAND D ODWYER PJ
Citation: Jp. Stevenson et al., A PHASE-I TRIAL OF IRINOTECAN AND TOMUDEX ON AN EVERY 3 WEEK SCHEDULE, Annals of oncology, 9, 1998, pp. 270-270
PHASE-I TRIAL OF THE DIARYLSULFONYLUREA LY295501 ADMINISTERED ON A WEEKLY X-3 SCHEDULE
Authors: DEMARIA D STEVENSON JP MITCHELL E ROSE L REDLINGER M KUNZ K NYHART E STORNIOLO AM ODWYER PJ
Citation: D. Demaria et al., PHASE-I TRIAL OF THE DIARYLSULFONYLUREA LY295501 ADMINISTERED ON A WEEKLY X-3 SCHEDULE, Annals of oncology, 9, 1998, pp. 438-438
NEW PRINTED-CIRCUIT-BOARD CHALLENGES
Authors: DEMARIA D
Citation: D. Demaria, NEW PRINTED-CIRCUIT-BOARD CHALLENGES, Electronic design, 46(8), 1998, pp. 84-84
A PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF THE NEW TOPOISOMERASEINHIBITOR GI147211 GIVEN AS A 72-H CONTINUOUS-INFUSION
Authors: PAZARES L KUNKA R DEMARIA D CASSIDY J ALDEN M BERANEK P KAYE S LITTLEFIELD D REILLY D DEPEE S WISSEL P TWELVES C ODWYER P
Citation: L. Pazares et al., A PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF THE NEW TOPOISOMERASEINHIBITOR GI147211 GIVEN AS A 72-H CONTINUOUS-INFUSION, British Journal of Cancer, 78(10), 1998, pp. 1329-1336
PHASE-I TRIAL OF THE THYMIDYLATE SYNTHASE INHIBITOR AG331 AS A 5-DAY CONTINUOUS-INFUSION
Authors: ODWYER PJ LAUB PB DEMARIA D QIAN MX REILLY D GIANTONIO B JOHNSTON AL WU EY BAUMAN L CLENDENINN NJ GALLO JM
Citation: Pj. Odwyer et al., PHASE-I TRIAL OF THE THYMIDYLATE SYNTHASE INHIBITOR AG331 AS A 5-DAY CONTINUOUS-INFUSION, Clinical cancer research, 2(10), 1996, pp. 1685-1692
PHASE-I TRIAL OF ETOPOSIDE, DOXORUBICIN AND CISPLATIN (EAP) IN COMBINATION WITH GM-CSF
Authors: FORD PA ARBUCK SG MINNITI C MILLER LL DEMARIA D ODWYER PJ
Citation: Pa. Ford et al., PHASE-I TRIAL OF ETOPOSIDE, DOXORUBICIN AND CISPLATIN (EAP) IN COMBINATION WITH GM-CSF, European journal of cancer, 32A(4), 1996, pp. 631-635
PHASE-I TRIAL OF THE TOPOISOMERASE-I INHIBITOR GG211 AS A 72-HOUR INFUSION
Authors: ODWYER P PASAREZ L KUNKA R DEMARIA D CASSIDY J KAYE S DEPEE S LITTLEFIELD D SELINGER K BERANEK P GRAHAM J WISSEL P
Citation: P. Odwyer et al., PHASE-I TRIAL OF THE TOPOISOMERASE-I INHIBITOR GG211 AS A 72-HOUR INFUSION, European journal of cancer, 31A, 1995, pp. 928-928
Risultati: 1-10 |